The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
 
Christine H. Chung
Consulting or Advisory Role - Exelixis; Merck; Sanofi/Regeneron
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Brooklyn ImmunoTherapeutics (Inst); Ignyta (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst)
 
A. Dimitrios Colevas
Consulting or Advisory Role - Alpha BioCom; Beigene; ClearView Healthcare Partners; Deallus; Gilead Sciences; leidos biomedical research
Research Funding - Abbvie; AstraZeneca; Atara Biotherapeutics; BioNtech; BMS; CUE Biopharma; Cullinan Oncology; Exelixis; Experimental Therapeutics Clinical Trials Network (ETCTN); Forty Seven; Innate Pharma; Merck; NIH/NCI; NRG Oncology; Tessa Therapeutics
 
Douglas Adkins
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Coherus Biosciences; CUE Biopharma; Eisai Europe; Exelixis; Immunitas; Kura Oncology; Merck; TargImmune Therapeutics; twoXAR; Vaccinex; Xilio Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Exelixis (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); Innate Pharma (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Matrix Biomed (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Rubius Therapeutics (Inst); Sensei Biotherapeutics (Inst); Shanghai Denovo (Inst); Vaccinex (Inst)
 
Michael K. Gibson
Consulting or Advisory Role - Abbvie; Flagship Biosciences; Soligenix
Speakers' Bureau - Bristol-Myers Squibb
 
Cristina P. Rodriguez
Consulting or Advisory Role - Abbvie (I); ADC Therapeutics (I); AstraZeneca (I); beigene (I); Coherus Biosciences; Incyte (I); Karyopharm Therapeutics (I); Kite, a Gilead company (I); Millenium Pharamceuticals (I); Millenium Pharamceuticals (I)
Research Funding - AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Denovo Biopharma (Inst); Genentech (Inst); Ignyta (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst)
 
Ammar Sukari
Stock and Other Ownership Interests - Bristol-Myers Squibb/Pfizer; Merck
Honoraria - Merck Serono
Consulting or Advisory Role - Genentech
Speakers' Bureau - Eisai
 
Julie E. Bauman
Research Funding - AstraZeneca (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CUE Biopharma (Inst); Lilly (Inst); Moderna Therapeutics (Inst); Novartis (Inst)
 
Lori J. Wirth
Consulting or Advisory Role - Bayer; Blueprint Medicines; Coherus Biosciences; Eisai; Exelixis; Lilly; Loxo; Merck; Morphic Therapeutic
Research Funding - Ayala Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); CUE Biopharma (Inst); Eisai (Inst); Lilly (Inst)
Expert Testimony - Eisai
Other Relationship - PDS Biotechnology
 
Faye M. Johnson
Honoraria - Emory University; Methodist Hospital
Research Funding - PIQUR; Takeda; Trovagene; Viracta Therapeutics (Inst)
 
Nabil F. Saba
Honoraria - BioNTech; CUE Biopharma; Merck
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Exelixis
Travel, Accommodations, Expenses - Blueprint Medicines; GlaxoSmithKline; Merck; Pfizer
 
Barbara Burtness
Consulting or Advisory Role - ALX Oncology; CUE Biopharma; Debiopharm Group; Exelixis; Genentech/Roche; IO Biotech; Ipsen; Kura Oncology; Macrogenics; Maverick Therapeutics; Merck; Merck KGaA; Nanobiotix; PPD Global; Rakuten Medical
Speakers' Bureau - Clinical Education Alliance; Oncology Education
Research Funding - AstraZeneca; CUE Biopharma (Inst); Eisai; Exelixis (Inst); Genentech; Kura Oncology; Merck; Merck (Inst); Nektar; Rakuten Medical
Travel, Accommodations, Expenses - Debiopharm Group; Merck
 
Lara Dunn
Consulting or Advisory Role - Merck
Research Funding - CUE Biopharma; Nektar; Regeneron; Replimune
 
Tanguy Y. Seiwert
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Aduro Biotech; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Celgene; Innate Pharma; Merck; Nanobiotix; Roche Molecular Diagnostics
Research Funding - Bristol-Myers Squibb (Inst); Jounce Therapeutics (Inst); Merck (Inst)
 
Francis P. Worden
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck Sharp & Dohme; Regeneron
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Loxo; Merck; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme
 
Jameel Muzaffar
No Relationships to Disclose
 
Steven Margossian
Employment - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma
Consulting or Advisory Role - Novartis Pharmaceuticals UK Ltd.
 
Raymond Moniz
Employment - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma; Merck
 
Steven N Quayle
Employment - Cue Biopharma; Pieris Pharmaceuticals (I)
Stock and Other Ownership Interests - Cue Biopharma; IQVIA (I); Pieris Pharmaceuticals (I)
 
Matteo Levisetti
Employment - Cue Biopharma; DNAtrix
Stock and Other Ownership Interests - Cue Biopharma
 
Sara I. Pai
Consulting or Advisory Role - CUE Biopharma; Merck; Parthenon Therapeutics; Replimune; Scopus BioPharma; Sensei Biotherapeutics
Research Funding - Abbvie; AstraZeneca/MedImmune (Inst); CUE Biopharma; Merck (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca/MedImmune; Merck